<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447577</url>
  </required_header>
  <id_info>
    <org_study_id>512</org_study_id>
    <nct_id>NCT00447577</nct_id>
  </id_info>
  <brief_title>Zylet vs TobraDex in Blepharokeratoconjunctivitis</brief_title>
  <official_title>A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in
      the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite score</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The distribution of Investigator global assessment at each visit.</measure>
    <time_frame>Visit 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of eyes that were considered improved or cured at each visit based on the Investigator global assessment.</measure>
    <time_frame>Visit 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to Day 7 (Visit 3) and to Day 3 (Visit 2) in the signs and symptoms composite score.</measure>
    <time_frame>Visit 2 &amp; 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to each visit in the signs composite score and the symptoms composite score.</measure>
    <time_frame>Visit 1, 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to each visit in the Blepharitis signs composite score, the conjunctivitis signs composite score, and the Keratitis signs composite score.</measure>
    <time_frame>Visit 1, 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to each visit in individual signs and symptoms.</measure>
    <time_frame>Visit 1, 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VA, Biomicroscopy, and IOP assessments at each visit</measure>
    <time_frame>Visit 1, 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Visit 1, 2, 3 &amp; 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Blepharokeratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Zylet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobradex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate and tobramycin ophthalmic suspension</intervention_name>
    <description>Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.</description>
    <arm_group_label>Zylet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin and dexamethasone ophthalmic suspension</intervention_name>
    <description>Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.</description>
    <arm_group_label>Tobradex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least 18 years of age

          -  Must be able and willing to comply with all treatment and follow up procedures

          -  Must have the ability to understand and sign an Informed Consent Form and provide
             Health Insurance Portability and Accountability Act (HIPAA) authorization

          -  Must be able to self-administer drugs

          -  Must have a clinical diagnosis of blepharokeratoconjunctivitis in at least one eye
             (total Ocular Signs and Symptoms score of at least 10, with at least one ocular sign
             and one ocular symptom each having a score of Grade 2 level or higher)

          -  Women of childbearing potential must be sexually inactive or using an approved birth
             control methods and must have a negative urine pregnancy test

          -  Must be willing to discontinue contact lens use for the duration of the study

          -  Must have pin-holed Snellen visual acuity equal to or better than 20/40 in both eyes

        Exclusion Criteria:

          -  Any uncontrolled systemic disease or debilitating disease (e.g. cardiovascular
             disease, hypertension, diabetes, or cystic fibrosis)

          -  Known hypersensitivity to the study drugs or their components (including benzalkonium
             chloride) or contraindications to tobramycin or ocular corticosteroids

          -  Use of any systemic or topical ophthalmic non-steroidal anti-inflammatory agents,
             analgesics, and antihistamines that cannot be discontinued during the study

          -  Use of any topical ophthalmic medications, including tear substitutes, within 2 hours
             before and that cannot be discontinued during the study

          -  Use of any systemic or topical ophthalmic antibiotic agents within 72 hours before and
             that cannot be discontinued during the study

          -  Use of any systemic or topical ophthalmic corticosteroid agents within 7 days before
             and that cannot be discontinued during the study

          -  Use of any systemic or topical ophthalmic mast cell stabilizers within 14 days before
             and that cannot be discontinued during the study

          -  Use of any topical ophthalmic immunosuppressant (e.g. Restasis) agents within 30 days
             before and that cannot be discontinued during the study

          -  Suspected preseptal cellulites, or any other disease conditions which the Investigator
             determines could interfere with the safety and efficacy evaluations of the study drug

          -  Suspected dacrocystitis

          -  Participation in an ophthalmic drug or device research study within the 30 days prior
             to entry in this study

          -  Ocular surgery (including laser surgery) in either eye within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Comstock, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornerstone Eye Care</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2007</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

